Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;10(2):892-898.
doi: 10.1007/s40615-022-01277-8. Epub 2022 Apr 5.

Clinical Trial Participation and COVID-19: a Descriptive Analysis from the American Heart Association's Get With The Guidelines Registry

Kevin S Shah  1 , Adriana E Reyes-Miranda  2 , Steven M Bradley  3 , Khadijah Breathett  4 , Sandeep R Das  5 , Ty J Gluckman  6 , Divya Gupta  7 , Daniel T Leung  8 , R Kannan Mutharasan  9 , Pamela N Peterson  10   11 , Emily S Spivak  8 , Rashmee U Shah  2
Affiliations

Clinical Trial Participation and COVID-19: a Descriptive Analysis from the American Heart Association's Get With The Guidelines Registry

Kevin S Shah et al. J Racial Ethn Health Disparities. 2023 Apr.

Abstract

As COVID-19 cases begin to decrease in the USA, learning from the pandemic experience will provide insights regarding disparities of care delivery. We sought to determine if specific populations hospitalized with COVID-19 are equally likely to be enrolled in clinical trials. We examined patients hospitalized with COVID-19 at centers participating in the American Heart Association's COVID-19 CVD Registry. The primary outcome was odds of enrollment in a clinical trial, according to sex, race, and ethnicity. Among 14,397 adults hospitalized with COVID-19, 9.5% (n = 1,377) were enrolled in a clinical trial. The proportion of enrolled patients was the lowest for Black patients (8%); in multivariable analysis, female and Black patients were less likely to be enrolled in a clinical trial related to COVID-19 compared to men and other racial groups, respectively. Determination of specific reasons for the disparities in trial participation related to COVID-19 in these populations should be further investigated.

Keywords: COVID-19; Disparities; Ethnicity; Race.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Enrollment in clinical trials by race and ethnicity. Proportion of hospitalized COVID-19 patients enrolled in clinical trials, stratified by race/ethnicity subgroup. Among 14,397 patients, n = 954 had unknown race/ethnicity. Group denominators as n = below each bar
See this image and copyright information in PMC

References

    1. Johns Hopkins Coronavirus Resource Center. Johns Hopkins Coronavirus Resource Center. Retrieved December 10, 2021 from https://coronavirus.jhu.edu/.
    1. Jimenez R, et al. Clinical trial participation among ethnic/racial minority and majority patients with advanced cancer: what factors most influence enrollment? J Palliat Med. 2013;16:256–262. doi: 10.1089/jpm.2012.0413. - DOI - PMC - PubMed
    1. Killien M, et al. Involving minority and underrepresented women in clinical trials: the National Centers of Excellence in Women’s Health. J Womens Health Gend Based Med. 2000;9:1061–1070. doi: 10.1089/152460900445974. - DOI - PubMed
    1. Hamel LM, et al. Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control. 2016;23:327–337. doi: 10.1177/107327481602300404. - DOI - PMC - PubMed
    1. Durant RW, et al. Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff and referring clinicians. Cancer. 2014;120:1097–1105. doi: 10.1002/cncr.28574. - DOI - PMC - PubMed

Publication types